Current ongoing trials with AbE as their primary or secondary outcome mainly investigate the combination of RT and the inhibition of the PD-1/PD-L1 pathway in various cancers such as NSCLC, metastatic gastro-intestinal cancer, metastatic melanoma and metastatic breast cancer (Table 5). The gene discussed is RPL17; the disease is cancer.